As part of its advocacy program in the United States, ACRO submits regulatory comments to US regulators. This comment letter, submitted by ACRO to FDA in 2018 about Docket No. FDA-2018-D-1893-0002, “Patient-Focused Drug Development: Collecting Comprehensive and Representative Input” can be found below.